Last mentioned: Mar 24, 2026
Operational Launch
The North Chicago facilities are expected to begin full-scale API production.
Evolysse Launch
Anticipated commercial rollout of the Evolysse dermal filler portfolio in the U.S.
Construction Start
Groundbreaking expected for the two new advanced manufacturing sites.
Earnings Release
Company reports Q4 beat and issues bullish 2026 revenue guidance.
Manufacturing Expansion
AbbVie announces $380M investment for North Chicago API facilities.
$100B Pledge
AbbVie commits to $100 billion in U.S. R&D and manufacturing over the next decade.
Q4 Fiscal Close
Evolus concludes its strongest fiscal year to date with record Jeuveau sales.
Belgian biopharma giant UCB has announced a massive $2 billion investment to establish a new manufacturing plant in suburban Atlanta, creating 330 high-skilled jobs. The move strengthens UCB's U.S. footprint as it scales production for its high-growth immunology portfolio.
Evolus reported record Q4 2025 financial results, triggering a significant stock rally following a revenue beat and robust 2026 guidance. The company's performance underscores the resilience of the medical aesthetics market and the growing adoption of its flagship neurotoxin, Jeuveau.
AbbVie has announced a $380 million investment to expand its North Chicago manufacturing campus, marking the first major step in a $100 billion decade-long commitment to U.S. R&D. The initiative aims to localize active pharmaceutical ingredient production while integrating with the Trump administration's 'TrumpRx' program to lower drug costs.
This page surfaces every story mentioning AbbVie across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where AbbVie was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |